The biosims of Herceptin probably can't even compete on price because Her-Vaxx is much cheaper to manufacture and administer. And to top that off, Her-Vaxx has a long patent runway.
I dare bet with this announcement, Roche is looking over their shoulders now. They are already suffering great decline in their revenue from Herceptin because of all these pesky biosims. Imagine losing the revenue totally because of Her-Vaxx. One wonder if Roche would allow that to happen!
Ann: Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials, page-113
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
0.002(4.65%) |
Mkt cap ! $334.7M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.5¢ | 4.3¢ | $732.0K | 16.76M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1799587 | 4.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 1003772 | 13 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |